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Simple Summary: Small-cell lung cancer accounts for approximately 13% of all new lung cancer
diagnoses, but in contrast to non-small-cell lung cancer, the implementation of targeted treatments in
small-cell lung cancer has been limited, with little improvement in the clinical outcome in the last
several decades. Exploring new pathways for targeted therapy, we have observed that extra-copies of
the tRNA modifier TRIT1, involved in the translation of selenoproteins, confers sensitivity to arsenic
trioxide in small-cell lung cancer. This finding could open a new therapeutic niche for a tumor type
with such a dismal clinical course.
Abstract: The alteration of RNA modification patterns is emerging as a common feature of human
malignancies. If these changes affect key RNA molecules for mRNA translation, such as transfer RNA,
they can have important consequences for cell transformation. TRIT1 is the enzyme responsible for
the hypermodification of adenosine 37 in the anticodon region of human tRNAs containing serine and
selenocysteine. Herein, we show that TRIT1 undergoes gene amplification-associated overexpression
in cancer cell lines and primary samples of small-cell lung cancer. From growth and functional
standpoints, the induced depletion of TRIT1 expression in amplified cells reduces their tumorigenic
potential and downregulates the selenoprotein transcripts. We observed that TRIT1-amplified cells
are sensitive to arsenic trioxide, a compound that regulates selenoproteins, whereas reduction of
TRIT1 levels confers loss of sensitivity to the drug. Overall, our results indicate a role for TRIT1 as a
small-cell lung cancer-relevant gene that, when undergoing gene amplification-associated activation,
can be targeted with the differentiation agent arsenic trioxide.
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1. Introduction
Altered RNA and protein patterns are a feature of human tumors. These aberrant
expression profiles may arise by myriad mechanisms. One interesting possibility is that the
dysregulated cancer transcriptome and proteome are linked to aberrant RNA modification
landscapes. RNA molecules exhibit chemically modified nucleosides that together form the
denominated epitranscriptome [1–3]. More than 100 differentially modified nucleotides,
affecting RNA stability, targeting, translation, and other activities have been reported. An
emerging body of data in cancer biology indicates that significant changes occur in the
epitranscriptome with the appearance of genetic and epigenetic defects in RNA-modifier
genes [1–3]. RNA modifications are particularly relevant in transfer RNA molecules
(tRNAs). These affect protein translation function at several levels, including amino acid
loading, wobbling or translation efficiency, and translational fidelity [4,5]. Importantly,
tRNA modifications and tRNA modifier enzymes are disrupted in a variety of human
diseases, including cancer [6–8].
One example of a chemical modification of tRNA with a putative role in tumorigenesis
is the appearance of hypermodified adenosines at position A37, adjacent to the anticodon
of serine (tRNASer) and selenocysteine (tRNA[Ser]Sec) tRNAs [9–11]. The A37 position in
the anticodon loop is modified to N6-isopentenyladenosine (i6A) by the tRNA isopentenyl-
transferase 1 (TRIT1) enzyme [10–12] and can be further hypermodified by CDK5RAP1,
which converts i6A to 2-methylthio-N6-isopentenyl adenosine (ms2i6A) [12–16]. The correct
hypermodification of A37 is essential for the specific activity of its associated tRNAs, which
regulate translation fidelity and efficiency [17]. A potential link to cancer involves the effect
of the hypermodified A37 on tRNA[Ser]Sec functionality and, thereby, on selenoprotein
synthesis [18]. Selenium-containing proteins fulfil pleiotropic roles in carcinogenesis, such
as the detoxification of reactive oxygen species, the modulation of calcium homeostasis
and unfolded protein responses in the endoplasmic reticulum [19,20], and the reduction in
selenoprotein expression due to the impairment of isopentenylated tRNAs [9,21]. These
findings prompted us to investigate the presence of genetic and epigenetic defects in the
A37-modifying enzymes TRIT1 and CDK5RAP1 in human tumors. Herein, we describe
how TRIT1 undergoes gene amplification-associated overexpression in cancer cell lines
and primary samples of small-cell lung cancer, giving rise to growth-inhibitory sensitivity
to arsenic trioxide.
2. Materials and Methods
2.1. Human Cell Lines
For this study, NCI-H82 (American Type Culture Collection, ATCC), DMS-273 (Sigma-
Aldrich, St. Louis, MO, USA) and HCC-33 (Leibniz Institute DSMZ, German Collection
of Microorganisms and Cell Cultures) human small-cell lung cancer (SCLC) cell lines,
and HEK293 (ATCC) human embryonic kidney cell line were used. NCI-H82, HCC-33,
and HEK293 cell lines were cultured with Roswell Park Memorial Institute (RPMI1640,
Gibco, Waltham, MA, USA) medium and, DMS-273 cell lines were cultured with Way-
mouth (Gibco, Waltham, MA, USA) medium. Culture medium was completed with 10%
fetal bovine serum (FBS, Gibco, Waltham, MA, USA) and 1% of penicillin/streptomycin
(Invitrogen, Carlsbad, CA, USA). Cells were cultured at 37 ◦C with 5% (v/v) of CO2. All
cell lines tested negative for mycoplasma.
2.2. Human Biological Samples
DNAs isolated from tumor samples of 39 SCLC patients obtained between 1975 and
2010 at the National Cancer Center Hospital/National Cancer Center Biobank (Tokyo,
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Japan), Saitama Medical University (Saitama, Japan), and the University of Tsukuba
(Ibaraki, Japan) were used in this study. The study was approved by the correspond-
ing Institutional Review Boards.
2.3. Fluorescence In Situ Hybridization (FISH)
The UCSC genome browser was used to select the 1p34.2 region probe RP11-613D14
for TRIT1 detection. Bacterial artificial chromosome (BAC) clones were obtained from
the BACPAC Resources Center at the Children’s Hospital Oakland Research Institute
(Oakland, CA, USA). Probe was labeled with Spectrum Red dUTP (Abbott, Chicago, IL,
USA) and CGH Nick Translation Kit with control DNA (MPE 600, Abbott, Chicago, IL,
USA). FISH was performed on cells fixed in Carnoy’s solution. The sample and probe
were codenatured by heating slides on a hotplate at 75 ◦C for 2 min. After that, they were
hybridized with 5 µL of handmade probe mixture (BAC RP11-613D14, 1p34.2/TRIT1) or
control (D-5099-100-OG, MetaSystems, 1p32.3) and incubated in a humidified chamber
at 37 ◦C overnight. Post-hybridization washes of hybridized slides were performed first
with 0.4X SSC (pH 7.0) at 72 ◦C for 2 min followed by a wash in 2X SSC, 0.05% Tween-20
(pH 7.0) at room temperature for 30 s. Finally, slides were counterstained with DAPI and
analyzed under a fluorescent microscope (NIKON, Eclipse E400).
2.4. Multiplex Ligation-Dependent Probe Amplification (MLPA)
DNA samples from SCLC patients and SCLC cell lines were sent to qGenomics (Spain)
for MLPA analysis. Two probes for exons 4 and 9 of the TRIT1 gene were designed. RAC1
(exon 6), TBCK (exon 15), TRPM7 (exons 17 and 18), and TRIP12 (exons 3 and 11) probes
were used as references.
2.5. TRIT1 Short-Hairpin RNA
Lentiviral plasmids for TRIT1 human shRNA (TL300819-C, Origene, Rockville, MD,
USA) and scrambled shRNA (TR30021, Origene, Rockville, MD, USA), both cloned in
pGFP-C-shLenti vector, were used. To obtain the lentiviral particles, 10 µg of plasmid were
mixed with 7.5 µg of ps-PAX2 and 2.5 µg of PMD2.G plasmid (Addgene, Watertown, MA,
USA), using jetPRIME® Transfection Reagent (Polyplus Transfection, New York, NY, USA).
The transfection mix was added to HEK293 cells at 80% confluence. After 72 h, medium
with high-titer lentiviral particles was 0.45 µm-filtered and DMS-273 cells were cultured in
virus containing medium for 24 h. After five passages, green fluorescent cells were sorted
by fluorescence-activated single cell sorting (FACS).
2.6. Western Blot
Cells were collected by scraping after two washes with cold PBS. Cell pellets were
resuspended in RIPA (0.1% SDS, 50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA,
1% NP-40, 12.23 mM deoxycholic acid) containing protease and the cOmplete™ (Roche,
Basel, Switzerland) phosphatase inhibitor cocktail, then incubated for 20 min on ice. The
tubes were centrifuged for 5 min at 13,000 rpm, and the supernatant was collected. RIPA
extracts were quantified using the Pierce™ BCA Protein Assay Kit (Thermo Scientific,
Waltham, MA, USA). Each sample was diluted 1:6 in water and 10 µL of each sample
were loaded in triplicate into a 96-well plate. A standard curve of albumin was performed
to determine protein concentration. Kit reagents were prepared and loaded according
to the manufacturer’s instructions. After 30 min, the 96-well plate was read at 562 nm.
TRIT1 protein expression was analyzed by Western blot. SDS-PAGE was performed on
acrylamide gels with an acrylamide percentage of 12%. Membranes were blocked with
5% skimmed milk (BD Difco, 232100) in 0.1% Tween-20 in PBS (PBS-Tween) for 1 h with
shaking. Membranes were incubated overnight at 4 ◦C with TRIT1 antibody (NBP2-20727,
Novus Biologicals, 1:1000 dilution). Afterwards, membranes were washed three times with
PBS-Tween and incubated with anti-rabbit HRP-conjugated secondary antibody (A0545,
Sigma Aldrich, St. Louis, MO, USA, 1:10,000 dilution) for 1 h with shaking. Membranes
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were washed three times with PBS-Tween and developed using Luminata HRP-substrates
(Millipore, Burlington, MA, USA). As a loading control, membranes were incubated with β-
actin (Actin) HRP-conjugated antibody (A3854, Sigma Aldrich, St. Louis, MO, USA, 1:5000).
2.7. N6-Isopentenyladenosine (I6A) Quantification
Cells were lysed using TRI Reagent (T9424, Sigma Aldrich, St. Louis, MO, USA)
and phase separation was performed with 1-bromo-3-chloropropane. The mixture was
centrifuged in order to obtain the aqueous phase and to precipitate the RNA with 2-
isopropanol. RNA pellets were washed with ethanol, dried, and resuspended in water.
The RNA concentration was measured with a Nanodrop (ThermoFisher, Waltham, MA,
USA) spectrophotometer. Modification status of A37 was finally determined by liquid
chromatography–mass spectrometry (LC/MS).
2.8. Murine Models
To analyze tumor growth, DMS-273 SCR or shTRIT1 cells were subcutaneously in-
jected into the flanks of five-week-old athymic nu/nu mice (Envigo Laboratories). Three
million cells in 50% Matrigel (354234, BD Biosciences) for each condition were injected
into nine mice per group. Tumor development was monitored every 4–6 days, and tu-
mor size (width: W and length: L) was measured with a caliper to calculate the volume
(V = π/6 × L ×W2). Animals were sacrificed 20 days after injection.
For the arsenic trioxide treatment, DMS-273 SCR or shTRIT1 cells were subcutaneously
injected in the mouse flanks as described above. Ten days after injection, the animals were
randomized in two groups and treated with vehicle (0.015 N NaOH in saline) or Arsenic
Trioxide (A1010, Sigma-Aldrich, St. Louis, MO, USA) diluted in 0.015 N NaOH. Drug was
administered by intraperitoneal injection at 5 mg/kg dosage following a schedule of 5 days
ON/2OFF for three consecutive weeks. Tumor growth was monitored and measured
as described above and animals were sacrificed 28 days after cell-line inoculation. All
mouse experiments were approved by the Institutional Animal Care Committee of Bellvitge
Biomedical Research Institute (IDIBELL) and performed in accordance with the guide-
lines of the International Guiding Principles for Biomedical Research Involving Animals,
developed for the Council for International Organizations of Medical Sciences (CIOMS).
The IDIBELL animal facility is accredited by the AAALAC (Association for Assessment
and Accreditation of Laboratory Animal Care International, Unit 1155) since 2006 and
works according to the European and National Legislation (CEE/86/609, RD1201/2005,
RD214/1997). Our experimental procedure (9111) was revised and approved by local
Government of Generalitat de Catalunya.
2.9. Drug-Dose Response Assay
After determining the optimal number, 20,000 cells were seeded onto 96-well
plates. After overnight incubation, cells were treated with decreasing concentrations
of arsenic trioxide (A1010, Sigma-Aldrich, St. Louis, MO, USA) or cisplatin (cis-
diammineplatinum(II)dichloride, P4394, Sigma-Aldrich, St. Louis, MO, USA) in order
to calculate the half-maximal inhibitory concentration (IC50). After 48 h, MTT (3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, Sigma-Aldrich, M2128-
10G) reagent was added. After 3 h of incubation at 37 ◦C, cells were lysed for about
20 h with MTT lysis buffer (50% N-N dimethylformamide, 20% sodium dodecyl sulfate,
2.5% glacial acetic acid, 2.1% 1 N HCl, at pH 4.7), and absorbance was read at 560 nm
with an optical spectrometer. IC50 was determined with GraphPad Prism (Version 5
for Windows, GraphPad Software, La Jolla, CA, USA).
2.10. RNA Sequencing
Total RNA from DMS-273 SCR and shTRIT1 cells was extracted using a Maxwell
RSC device (Promega, Madison, WI, USA). Then, 5 µg of total RNA from three biological
replicates from each sample were used for RNA sequencing (RNA-seq). The RNA-seq
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libraries were prepared from total RNA with TruSeq®Stranded mRNA LT Sample Prep Kit
(Illumina, San Diego, CA, USA). Each library was sequenced using a TruSeq SBS Kit v4-HS,
in paired-end mode with a read length of 2 × 76 + 8 + 8bp. We obtained ~500 million
paired-end reads in a fraction of a sequencing lane on HiSeq2500 (Illumina, San Diego,
CA, USA), following the manufacturer’s protocol. Raw reads were quality assessed and
preprocessed using FASTQC (version 0.11.7, Babraham Bioinformatics, Babraham Institute,
Cambridge, UK) and Trimmomatic (version 0.36, The Usadel Lab, Aachen University,
Aachen, Germany) software. Differential expression analysis was performed using DESeq2
Bioconductor package (v1.18.1), in R (v3.4.3). Gene annotations were extracted from
GENECODE (v35). Gene ontology (GO) biological processes for the downregulated genes
with a log2-fold change >|1| and a false discovery rate (FDR) adjusted p-value < 0.05
included in the GSEA signature database were used to perform an enrichment analysis.
2.11. Statistical Analysis
Associations between variables were assessed by Student’s t test and Wilcoxon rank
sum test. Statistical analyses were carried out with GraphPad Prism 5 for Windows (La
Jolla, CA, USA). Values of p < 0.05 were considered statistically significant (* p < 0.05;
** p < 0.01; *** p < 0.001). All statistical tests were two-sided. The values corresponding to
TRIT1 copy number and expression in cell lines were obtained from the Broad Institute
Cancer Cell Line Encyclopedia (CCLE) (https://depmap.org/portal/download/ Public
Release 20Q4, accessed on 13 January 2021).
3. Results
3.1. Detection of TRIT1 Gene Amplification-Associated Overexpression in Small-Cell Lung Cancer
Cell Lines
To find tumor-associated genetic and epigenetic changes in the A37-modifying
enzymes TRIT1 and CDK5RAP1 (Figure 1A), we data-mined a collection of about
1000 human cancer cell lines in which the transcriptome, DNA methylation landscape,
exome sequence, and gene copy number were available [22,23]. The available multi-
omics data did not reveal the presence of TRIT1 or CDK5RAP1 mutations, deletions, or
promoter hypermethylation events in the analyzed cell lines (Supplementary Materials
Dataset S1). However, the TRIT1 gene was found to be amplified in 18.3% (11 of 60) of
small-cell lung cancer cell lines (Figure 1B and Supplementary Materials Dataset S1).
Gene amplification did not occur in the other tumor types. Data-mining of the available
RNA expression patterns in the described set of small-cell lung cancer cell lines [23]
demonstrated that TRIT1 gene amplification was associated with the overexpression of
its mRNA (Figure 1C). Related to the genetic context, small-cell lung cancer is highly
mutated at the RB1 and TP53 tumor suppressor genes. We observed that 82% (9 of 11)
and 100% (11 of 11) of the TRIT1 amplified cell lines showed RB1 and TP53 mutations,
respectively; an indistinguishable distribution to the one found in the non-amplified
cell lines (Fisher’s exact test, p = 0.4781 and p = 1, respectively).
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Germany), using a CGH Nick Translation Reagent Kit (Abbott Molecular Inc., Des Plaines, IL, USA). The samples were 
counterstained with DAPI and analyzed under a fluorescent microscope (NIKON, Eclipse E400). Gene amplification was 
found in the interphases of DMS-273 and HCC-33. The D-5099-100-OG probe (1p32.3, MetaSystems) was used as control. 
TRIT1/Control ratios are shown. (E) Multiplex ligation-dependent probe amplification (MLPA) assay. Probe mixes con-
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Having found the above-described TRIT1 copy-number patterns, we proceeded to
study TRIT1 gene amplification and its associated expression in detail in the small-cell
cancer lines NCI-H82, DMS-273 and HCC-33 that were included in the characterized
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set [22,23]. Using fluorescence in situ hybridization (FISH), we observed the presence of
TRIT1 gene amplification in the DMS-273 and HCC-33 cell lines, whereas NCI-H82 showed
the expected two copies of the genes (Figure 1D). These data confirmed the copy-number
results obtained from the whole exome sequencing (WES) data-mining (Supplementary
Materials Dataset S1). The use of multiplex ligation-dependent probe amplification (MLPA)
technology confirmed the occurrence of TRIT1 gene amplification in DMS-273 and HCC-33
cells and its absence in NCI-H82 cells (Figure 1E). Most notably, the presence of TRIT1 gene
amplification was associated with the overexpression of the TRIT1 protein in the DMS-273
and HCC-33 small-cell lung cancer cell lines determined by western-blot (Figure 1F) and
immunocytochemistry (Figure S1).
3.2. Cellular and Molecular Effects of TRIT1 Depletion in Gene Amplified Small-Cell Lung
Cancer Cells
Once we had demonstrated the existence of TRIT1 gene amplification-associated
overexpression in small-cell lung cancer cell lines, we interrogated its role in in vivo tumor
growth and its impact on i6A-tRNA-associated activity. To these ends, we downregulated
the expression of TRIT1 in the gene-amplified DMS-273 cell line. The efficient depletion
of TRIT1 by the short hairpin RNA approach was confirmed by Western blot (Figure 2A).
We first characterized the capacity of shRNA-depleted TRIT1 (shTRIT1) DMS-273 cells
to form subcutaneous tumors in nude mice compared with shRNA-scramble (SCR) cells.
The downregulation of TRIT1 levels in these small-cell lung tumors reduced their growth
in comparison with shRNA-scramble DMS-273-derived tumors, as demonstrated by the
continuous measurement of the tumor volume (Figure 2B).
Following the demonstration of how TRIT1 loss impaired tumor growth, we ana-
lyzed its effect on the chemical modification status of A37 using tRNA-associated liquid
chromatography–mass spectrometry (LC/MS) [24]. We found that shRNA-mediated down-
regulation of TRIT1 in DMS-273 cells induced a decrease in levels of the i6A nucleoside
(Figure 2C), as expected given the known function of the enzyme [10–12]. We then won-
dered whether the depletion of i6A content in these TRIT1 shRNA-downregulated cells
had any impact on the underlying transcriptome profile due to the deficient hypermodifi-
cation of the tRNAs containing this particular nucleoside. To address this, we carried out
RNA-seq in the shRNA-scramble DMS-273 cells harboring the amplified TRIT1 gene and
cells derived from them that exhibited shRNA-mediated depletion of the TRIT1 transcript.
DMS-273 shRNA-scramble and shRNA TRIT1 RNA-seq data have been deposited in the
Sequence Read Archive repository (SRA) under project code PRJNA692378. We found that
inducing TRIT1 depletion in the cells featuring gene amplification altered the levels of
4510 mRNAs (Table S1). This mostly took the form of downregulation, which occurred
in 75.6% (3409 of 4510) of mRNAs (Figure 2D). Importantly, of the 25 proteins containing
selenocysteine described in human cells, seven were found to be downregulated upon
depletion of TRIT1 (hypergeometric test, p = 0.00238), reinforcing the concept that defects in
isopentenylated tRNAs reduce selenoprotein expression [9,21]. The downregulated seleno-
proteins were GPX1, GPX3, GPX4, SELENON, SELENOP, SELENOW, and TXNRD1. Gene
set enrichment analysis (GSEA) assessed by gene ontology (GO) signature collections in the
group of downregulated RNAs demonstrated as the first category an overrepresentation of
the GO biological process “regulation of cell differentiation” (Figure 2E).
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downregulation of TRIT1 levels in these small-cell lung tumors reduced their growth in 
comparison with shRNA-scramble DMS-273-derived tumors, as demonstrated by the con-
tinuous measurement of the tumor volume (Figure 2B). 
 
Figure 2. Effect of TRIT1 depletion on tumor growth and the RNA transcriptome of small-cell lung cancer. (A) Stable 
downregulation of the TRIT1 gene by short hairpin RNA in the small-cell lung cancer cell line DMS-273 (shTRIT1) deter-
mined by western blot analysis. SCR, scramble shRNA. (B) Effect of TRIT1 shRNA-mediated depletion on the growth of 
Figure 2. Effect of TRIT1 depletion on tumor growth and the RNA transcriptome of small-cell lung cancer. (A) Stable
downregulation of the TRIT1 gene by short hairpin RNA in the small-cell lung cancer cell line DMS-273 (shTRIT1)
determined by western blot analysis. SCR, scramble s RNA. (B) Effect of TRIT1 shRNA-mediated depletion on the growth
of subcutaneous tumors in nude mice derived from DMS-273 cells (amplified and overexpressing TRIT1). There was a
significant reduction in tumor volume in the TRIT1 shRNA-depleted cells. Data are sum arized as the mean and standard
deviation (n = 9). Student’s t test, ** p < 0.01. (C) Nucleoside analysis of tRNAs by LC/MS showing that shRNA-mediated
depletion of TRIT1 in DMS-273 cells induces the depletion of the i6A-modified nucleoside. Student’s t test, *** p = 0.0002.
(D) Volcano plot summarizing the results of the RNA-seq experiment to find mRNAs differentially expressed in TRIT1
shRNA-depleted DMS-273 cells compared with scramble-shRNA DMS-273 cells. (E) Gene ontology (GO) analysis of
Biological Process categories in the transcripts downregulated on TRIT1 depletion in DMS-273 cells shows the GO Biological
Process category “regulation of cell differentiation” to be the most highly enriched.
3.3. Occurrence of TRIT1 Gene Amplification in Small-Cell Lung Cancer Patients and In Vitro and
In Vivo Sensitivity to Arsenic Trioxide
The occurrence of TRIT1 gene amplification was not an event confined to in vitro-
grown small-cell lung cancer cell lines, but was also observed in primary tumor samples.
We identified TRIT1 gene amplification in 10.3% (4/39) of primary small-cell lung cancer
cases. The clinicopathological features are summarized in Table 1. Examples of the MLPA
assay in small-cell lung cancer patients are shown in Figure 3A. The presence of extra copies
of TRIT1 was not associated with patient gender, smoking status, or clinical stage (Table 1).
Stage IV, which accounts for 85% of cases at diagnosis, was not enriched in our cohort, being
a potential limitation of our study. The distribution of RB1 and TP53 mutations [25] was
not different between TRIT1 amplified and non-amplified cases (Fisher’s exact test, p = 1).
TRIT1 gene amplification was not associated with overall survival (hazard ratio = 0.625;
p = 0.449; 95% CI = 0.185–2.113; log-rank test, p = 0.445). Expression microarray data were
available for six of these small-cell lung cancer cases [26]. For this subset of six samples, we
observed that the only patient with TRIT1 gene amplification showed the highest TRIT1
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expression levels, whereas the remaining five cases without TRIT1 extra-copies showed
lower expression (Figure 3B). We expanded these numbers by datamining a collection
of 68 small-cell lung cancer cases where SNP microarray data are available [27]. TRIT1
gene amplification was observed in 14.7% (10/68) of primary small-cell lung cancer cases
in this dataset. Expression microarray data were available for 23 cases of the described
cohort [27]. For this subset, the presence of TRIT1 gene amplification (observed in three
cases) was correlated with higher TRIT1 expression levels (Spearman’s correlation test,
p = 0.05). The distribution of RB1 and TP53 mutations [28] was not different between TRIT1
amplified and non-amplified cases (Fisher’s exact test, p = 1). We also wondered about the
distribution of TRIT1 gene amplification according to the small-cell lung cancer molecular
subtypes ASCL1, NEUROD1, POU2F3, and YAP1 [29]. Among the 23 cases available for
expression patterns, we found that the three cases with TRIT1 gene amplification occurred
all in the ASCL1 subtype.
Table 1. Clinicopathological features of the studied small cell lung cancer patients according to TRIT1 gene amplification status.








Age years [median (range)] 65 (49–84) 65 (49–84) 65 (55–71)
Gender
Female 8 (20.5%) 7 (20.0%) 1 (25.0%) 1.000
Male 31 (79.5%) 28 (80.0%) 3 (75.0%)
Smoker
Yes 33 (84.6%) 29 (82.9%) 4 (100.0%) 1.000
No 3 (7.7%) 3 (8.6%) 0 (0.0%)
Unknown 3 (7.7%) 3 (8.6%) 0 (0.0%)
Stage
I 10 (25.6%) 7 (20.0%) 3 (75.0%) 0.098
II 4 (10.3%) 4 (11.4%) 0 (0.0%)
III 11 (28.2%) 10 (28.6%) 1 (25.0%)
IV 14 (35.9%) 14 (40.0%) 0 (0.0%)
Type of clinical disease
Localized 18 (46.2%) 15 (42.9%) 3 (75.0%) 0.318
Extensive 21 (53.8%) 20 (57.1%) 1 (25.0%)
* p-value represents Fisher’s exact test or X2.
Since there are few therapeutic options for treating this malignancy and little evidence
that they have improved outcomes in recent years [30,31], we wondered whether the
copy number gain of TRIT1 is associated with an increased sensitivity to antitumor drugs.
Arsenic trioxide could be one such candidate compound [32,33]. It is highly effective in
the treatment of acute promyelocytic leukemia (APL) [34] and has shown considerable
therapeutic potential for treating other malignancies [32,33], including lung cancer [35].
The effect of arsenic trioxide in APL involves inducing differentiation of the leukemia
cells [34], the “differentiation” category being the most overrepresented in the GO analysis
of TRIT1-disrupted cells (Figure 2E). Most significantly, the downregulation of selenopro-
teins, observed in TRIT1-depleted cells (Table S1), induces loss of sensitivity to arsenic
trioxide-mediated cytotoxicity [36], and arsenic trioxide inhibits selenoprotein activity [37]
and synthesis [38]. In this regard, there is also an emerging interest in targeting selenopro-
teins for therapeutic purposes [39]. All these observations prompted us to assess whether
TRIT1 expression levels were associated with arsenic trioxide sensitivity. Using the model
of TRIT1 shRNA-mediated downregulation and the calculation of IC50 values according to
the MTT assay, we found that DMS-273 scramble shRNA cells overexpressing the TRIT1
gene were significantly more sensitive to the growth-inhibitory effect mediated by arsenic
trioxide than were TRIT1-depleted cells (Figure 3C). The effect was specific to the arsenic
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trioxide drug and we found no difference in the sensitivity to cisplatin between the two
cell lines (Figure 3C), a chemotherapy agent commonly used in the clinical treatment of
small-cell lung cancer. We extended the in vitro cell viability experiments to the in vivo
mouse model described above, and found that DMS-273 scramble shRNA-derived tumors
that harbored gene amplification-associated overexpression of TRIT1 responded markedly
to the administration of arsenic trioxide, whereas the shRNA-mediated depletion of TRIT1
abolished the growth-inhibitory effect of arsenic trioxide, whereby the tumors underwent
a similar increase in volume to those of the animals treated with the simple drug vehicle
(Figure 3D). Thus, these results suggest that small-cell lung cancers carrying extra copies of
TRIT1 are probably responders to arsenic trioxide.




Figure 3. TRIT1 gene amplification in primary small-cell lung cancer patients and response to arsenic trioxide. (A) MLPA 
assay of primary small-cell lung cancer samples. Probe mixes contained two probes for exons 4 and 9 of the TRIT1 gene 
(in orange). Six reference probes were also included (in grey). Values greater than 2 (two copies, corresponding to MLPA 
ratio of 1) were considered to indicate the presence of extra copies. Patient 1241 is shown as example of a TRIT1 two copy 
number case, whilst patient 391 shows TRIT1 gene amplification. (B) TRIT1 RNA expression levels derived from Affymet-
rix U133Plus2.0 microarray data in six primary small-cell lung cancer samples where TRIT1 copy number was determined. 
The only patient that exhibited TRIT1 gene amplification (#012) showed the highest TRIT1 expression level. Two copies of 
TRIT1 were observed in the 006, 010, 011, 014 and 018 samples. (C) IC50 determination by MTT assay. TRIT1 shRNA-
depleted DMS-273 cells were significantly less sensitive to the antiproliferative effect of arsenic trioxide than were the 
shRNA scramble-transfected cells harboring TRIT1 gene amplification-associated overexpression. TRIT1 shRNA-medi-
ated depletion did not affect sensitivity to cisplatin. Student’s t test, ** p < 0.01; ns, non-significant. (D) shRNA scramble 
(SCR, left panel) and TRIT1 shRNA-depleted (shTRIT1, right panel) DMS-273 cells were injected into the flanks of nude 
mice to form subcutaneous tumors. Tumor volume over time according to treatment conditions, vehicle (black lines) vs. 
arsenic trioxide-treated group (red lines) are shown. Black arrow indicates the time at which the mice were randomized 
and started to be treated with arsenic trioxide or vehicle. P values are those corresponding to Student’s t tests. Means and 
standard deviations (bars) are illustrated. Tumors derived from shRNA scramble-transfected DMS-273 cells were sensitive 
to the growth inhibition effect of arsenic trioxide (left panel), whilst TRIT1 shRNA-mediated depletion eliminates the 
enhanced sensitivity to arsenic trioxide, the tumor size reduction effect being similar to that obtained with the vehicle 
treatment (right panel). * p < 0.05; ns, non-significant. 
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and started to be treated with arsenic trioxide or vehicle. P values are those corresponding to Student’s t tests. Means
and standard devia ions (bars) are illustrated. Tumors derived from shRNA scramble-transfected DMS-273 cells were
sensitive to the growth inhibition effect of arsenic trioxide (left panel), whilst TRIT1 shRNA-mediated depletion eliminates
the enhanced sensitivity to arsenic trioxide, the tumor size reduction effect being similar to that obtained with the vehicle
treatment (right panel). * p < 0.05; ns, non-significant.
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4. Discussion
Small-cell lung cancer is an aggressive malignancy in which a majority of patients at
first diagnosis already show metastatic disease outside the hemithorax [30,31]. It accounts
for approximately 13% of all new lung cancer diagnoses, but in contrast to non-small-cell
lung cancer the implementation of targeted treatments in small-cell lung cancer has been
limited, with chemotherapy having been the standard therapy for first- and second-line
clinical management for several decades [30,31]. One of the main issues is the appearance
of chemoresistance at recurrence, a type of sample that was not included in our study.
One reason for the slow development of gene-oriented therapeutic approaches is that if
there are non-small-cell lung cancer cases with driver oncogenic-activating genetic events
(such as in the EGFR, ALK, and ROS genes) [40], small-cell lung cancer exhibits mostly
loss-of-function events in its pathogenesis (such as mutations in the tumor suppressor
genes RB1 or TP53). These molecular lesions could be targeted by drugs derived from
synthetic lethal screenings against these antioncogenes, but there has been little clinical
success in this area. As for other human tumor types, it would be best to act on an amplified
oncogene with a specific compound. In small-cell lung cancer, we would like to propose
that the gene amplification-associated overexpression of the tRNA modifier TRIT1 could
be an optimal bona fide target candidate in this context. Although there are no publicly
available small compound inhibitors of TRIT1 enzymatic activity, arsenic trioxide, through
its direct effects on selenium-containing proteins [36,38], is potentially effective in small-cell
lung cancer cells with high levels of TRIT1. The final cellular effects of the agent in cancer
cells involve induction of differentiation in the case of its approved use in APL [34] which
was the most highly enriched gene ontology category in our TRIT1 shRNA experiment.
However, more general mechanisms involving apoptosis and overall cytotoxicity can also
be invoked in human malignancies [32,33]. In this regard, arsenic trioxide has several
intracellular targets beyond selenoproteins. Interestingly, the expression levels of SOX2,
a recognized oncogene in small-cell lung cancer [41], are downregulated upon arsenic
trioxide in lung cancer cells [42] and we have also observed downregulation of SOX2 upon
TRIT1 shRNA-mediated depletion (Table S1), reinforcing again the link between TRIT1
and arsenic trioxide. For non-small-cell lung cancer, preclinical in vitro data suggest its
potential antitumor role [35], but it can be in the setting of small-cell lung cancer with the
use of TRIT1 gene amplification as an associated biomarker in which its true therapeutic
value for solid malignancies may be revealed. Arsenic trioxide can be administered by
intravenous infusion or orally, but it is an optimal candidate for conversion to a biocompat-
ible nanoparticulate form that would reduce the required dose, limiting any adverse effects
of the bulk form [32]. Beyond arsenic trioxide, other drugs could also be more active in
small-cell lung tumors harboring TRIT1 gene amplification. For example, data-mining the
Sanger collection of cancer cell lines where the IC50 values for 265 drugs are available, we
observed that small-cell lung cancer cells with TRIT1 extra-copies of TRIT1 were also sensi-
tive to dimethyloxalylglycine (DMOG), a competitive inhibitor against all 2-OG-dependent
dioxygenases (Figure S2).
In addition to expanding the role of the epitranscriptome in tumorigenesis [1,2], il-
lustrated here by the described tRNA modification, another aspect of the TRIT1 gene
amplification in small-cell lung cancer might have an additional impact on the treatment
of this malignancy. The first significant improvement in the clinical outcome of small-cell
lung cancer in several decades is the recent addition of immune checkpoint blockade to
the therapeutic arsenal against the disease [30,31]. This led the US Food and Drug Ad-
ministration to approve the use of the anti-PD-L1 inhibitor atezolizumab in combination
with carboplatin plus etoposide chemotherapy to treat extensive-stage disease [43]. A
significant clinical improvement was subsequently reported for the combination of dur-
valumab plus platinum-etoposide [44]. These results are very encouraging, although the
observed clinical effect has often been modest [43,44]. Thus, it is important to identify
the subset of cases that would respond best to the immunotherapy. In this regard, tumor
mutational burden (TMB) and PD-L1 expression are proposed as predictive markers of
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response to immune checkpoint inhibitors (ICIs) in human tumors, including small-cell
lung cancer [45,46], although other recent studies have not reported the association of these
biomarker with clinical benefit in extensive small-cell lung cancer treated with ICIs [47,48].
Interestingly, the 3′-untranslated region of TRIT1 contains an open reading frame in the
amplified region that generates a peptide recognized by cytotoxic T lymphocytes, leading
to the lysis of melanoma cells [49]. Thus, a hypothetical role of TRIT1 gene amplification in
immunotherapy is worthy of further investigation.
5. Conclusions
Overall, our results show that the tRNA modifier gene TRIT1 undergoes gene
amplification-associated overexpression in small-cell lung cancer cell lines and primary
samples. It is an aberrant genomic lesion that promotes tumor growth and is associated
with imbalance of the hypermodified adenosine adjacent to the anticodon of seleno-
cysteine tRNAs, and dysregulates the expression levels of selenoproteins that exert
pleiotropic functions in tumorigenesis. In vitro and in vivo data indicated that extra
TRIT1 copies confer sensitivity to the differentiating drug arsenic trioxide, providing
a new candidate therapeutic niche that merits further research, especially for a tumor
type with such a dismal clinical outcome.
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